ClinicalTrials.gg
RecruitingNCT07012304Updated Jun 10, 2025

Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

A Phase 1/2 interventional study of Gecacitinib Hydrochloride Tablets in Chronic Graft Versus Host Disease, sponsored by Yujun DONG. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by Yujun DONG · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Bronchiolitis Obliterans Syndrome with a site in China — 19 open to participants now, 25 under way, 2 of them phase 3. Bronchiolitis Obliterans Syndrome · China.

Planned enrollment
33rd of 42
24 · median 50
Started
2025
with 9 others
Phase 1/2
5 of 52
1 open now
Primary completion
2027-02
later than 11 of 24 live
Registered
37th of 52
by date

Among the 52 studies in Bronchiolitis Obliterans Syndrome with a site in China, this one is the 33rd largest by planned enrollment of the 42 interventional ones that give a count, is one of 10 that started in 2025, is one of 5 in phase 1/2, reaches primary completion later than 11 of the 24 other live ones, and was the 37th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

19 of the 52 studies in Bronchiolitis Obliterans Syndrome with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Bronchiolitis Obliterans Syndrome with a site in China, or all of them as a file.
02

Study summary

Chronic Graft-versus-Host Disease (cGVHD) is a common late complication following allogeneic hematopoietic stem cell transplantation and a leading non-relapse cause of death. It is often treatment-refractory, significantly affecting patients' quality of life and prognosis. This study will evaluate the feasibility, safety, and tolerability of gecacitinib, a novel JAK and ACVR1 inhibitor, in 24 patients with moderate-to-severe cGVHD who have undergone two or more prior therapies. Participants will receive gecacitinib hydrochloride tablets for at least 24 weeks. Patients demonstrating disease stability, as assessed by the investigator, may continue treatment with the study drug until week 60, unless intolerability, disease progression, or initiation of new systemic therapy, whichever occurs first.

03

Conditions studied

  • Chronic Graft Versus Host Disease

Keywords

  • cGVHD
  • JAK inhibitor
  • Gecacitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily Signed and aged ≥18 years
  • Undergone nonmyeloablative, myeloablative, or reduced-intensity using bone marrow, peripheral blood stem cells, or umbilical cord blood from any donor source
  • Confirmed myeloid and engraftment: >1.0×10⁹/L and platelet count >25×10⁹/L; no hematopoietic growth factors or blood product transfusions within 7 days before screening
  • Clinically diagnosed moderate-to-severe cGVHD according to the 2014 NIH
  • Received 2-5 prior systemic cGVHD therapies with persistent disease
  • PS score of 0-2
  • Able to swallow tablets
  • Concomitant use of non-interacting permitted

Exclusion criteria

Exclusion Criteria:

  • Recurrence of or loss of full donor chimerism
  • Concurrent use of other JAK inhibitors, mesenchymal stem cells, or belumosudil (Eligible if discontinued for >8 weeks post-aGVHD treatment or stopped JAK inhibitors for cGVHD due to side effects.)
  • Severe pulmonary cGVHD ( ≤39% or NIH lung symptom score of 3)
  • Post-transplant lymphoproliferative disease
  • Significant abnormalities affecting safety assessment, such as uncontrolled hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg) despite ≤2 antihypertensives; /AST >3×; DBIL/ >1.5×ULN; serum creatinine >1.5×ULN
  • History of major cardiovascular events within 6 months.
  • Arrhythmia requiring treatment at screening
  • Gastrointestinal conditions impairing drug absorption
  • Surgery within 4 weeks of screening with incomplete recovery
  • Active/uncontrolled infections (viral, bacterial, parasitic, fungal) requiring treatment
  • Active tuberculosis within 6 months
  • Epilepsy or use of psychotropic/sedative drugs
  • Pregnant/breastfeeding or unwilling to use during and 4 weeks post-study
  • Malignancy within 5 years (except the indication for transplant)
  • Use of anticoagulants/ inhibitors (except low-molecular-weight heparin)
  • Herbal medicine use within 1 week prior to enrollment
  • to gecacitinib or its components
  • Participation in another clinical trial within 4 weeks (or 5 half-lives of the previous study drug, whichever is longer)
  • Deemed unsuitable by the investigator
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Gecacitinib

    Drug: Gecacitinib Hydrochloride Tablets

Interventions

  • DrugJaktinibStudies of JaktinibJaktinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Gecacitinib hydrochloride tablets are taken orally on an empty stomach. The starting dose is 50 mg once daily (QD). The maximum dose is 100 mg twice daily (BID), and the minimum dose is 50 mg every other day (QOD). Dose adjustments should be made in 50-mg increments or decrements.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) at Week 24

    ORR was defined as the proportion of patients achieving complete response (CR) or partial response (PR) without requiring additional systemic therapy for cGVHD.

    Time frame: Week 24

Secondary outcomes

  1. ORR at Week 12, 48 and 60

    Time frame: week 12, 48 and 60

  2. Failure-free Survival (FFS)

    Time frame: Up to 24 months

  3. Change From Baseline in Lee cGVHD Symptom Scale Scores

    Subscale scores and the summary score range from 0 to 100, with a higher score indicating worse symptoms.

    Time frame: Through study completion, an average of 24 months

  4. Best Overall Response (BOR)

    Time frame: Up to week 24

  5. Duration of Response (DOR)

    Time frame: Up to 24 months

  6. Percentage of Participants With a ≥50% Reduction in Daily Corticosteroid Dose for ≥4 Weeks

    Time frame: Up to Day 180

  7. Relapse Rate

    Time frame: Up to 24 months

  8. Overall Survival (OS)

    Time frame: Up to 24 months

  9. Change from Baseline in FACT-BMT

    The FACT-BMT (Functional Assessment of Cancer Therapy-Bone Marrow Transplant) total score ranges from 0 to 148. Higher scores reflect a better quality of life.

    Time frame: Through study completion, an average of 24 months

  10. Change from Baseline in EQ-5D-5L

    The EQ-5D-5L (EuroQol 5-Dimension 5-Level Questionnaire) assesses health across five dimensions using five severity levels. It also includes a Visual Analogue Scale (VAS) ranging from 0 (worst imaginable health) to 100 (best imaginable health), where a higher score indicates a better health outcome.

    Time frame: Through study completion, an average of 24 months

  11. Adverse Events (AEs) and Adverse Drug Reactions (ADRs)

    Time frame: Up to 28 days after the last dose

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Feb 2027, 19 months later.

Of 24 phase 1/2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 87. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2025
First posted
Jun 10, 2025
StartEst.
Jun 30, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2029
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07012304
Lead sponsor
Yujun DONG
Responsible party
Yujun DONG (Director of the Hematology Department, Peking University First Hospital) — Sponsor-investigator
First posted
Jun 10, 2025
Start date
Jun 30, 2025 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Jun 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion